On January 30, Regeneron (Regeneron) Announces Acquisition of 2seventy bio, Obtains LatterDrugDiscovery PlatformAnd Clinical ProductionFlatPlatform and itsAll development and commercialization rights for the novel immunocyte therapies in the pipeline. And, Regeneron willEstablish a New DepartmentRegeneron Cell Medicines, to advance the development of acquired projects and its own cell therapy programs。The transaction is expected to be completed in the first half of 2024.。In 2018, Regeneron and bluebird bio (which spun off 2seventy bio in 2021) reached an agreement to collaborate on developing new cell therapies for cancer treatment. According to the initial agreement, Regeneron had the option to join.Projects Generated by Collaborative TargetsCo-development/co-commercialization efforts.According to the latest terms of the acquisition agreement, Regeneron will obtain full development and commercialization rights to 2seventy bio's preclinical and clinical pipeline projects and will assume responsibility for other projects related to these programs as well as associated infrastructure and personnel costs.RegeneronWill pay 2seventy bio$5 millionAdvance payment, and pay upon the first product's initial approvalA milestone paymentRegeneron will also pay 2seventy bio low single-digit tiered royalties on marketed product revenue.In order to fully utilize2s2seventy bio'sProjects andPlatformPotential: The new department, Regeneron Cell Medicines, will advance the development of next-generation cell therapies and explore the potential of combining these programs with Regeneron's antibody drugs. Additionally,Current Chief Scientific Officer of 2seventy bioPhilip GregoryWill be appointed as Senior Vice President and Head of Regeneron Cell Medicines upon completion of the transaction.Co-Chairman of the Board, Co-Founder, President and Chief Scientific Officer of RegeneronGeorge D. Yancopoulos"Regeneron and 2seventy are both committed to pushing the boundaries of science to develop therapies that can improve people's lives. Our antibody technology platform and expertise in emerging genetics, combined with 2seventy's cell therapy technology platform, will create opportunities to address the needs of cancer and other serious diseases in new and impactful ways.""By integrating 2seventy bio's cell therapy pipeline and its talented team, we are enhancing our own expertise and innovative immuno-oncology therapy portfolio, which could create truly transformative therapies that change patients' lives."Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
